Massey, Tricycle Gardens bring fresh produce to cancer patients
Research continues to show that proper nutrition plays an important role in cancer prevention and control. To help provide cancer patients access to fresh vegetables, VCU Massey Cancer Center has partnered with Richmond-based urban farm Tricycle Gardens to establish a monthly farm stand outside of Massey’s Dalton Oncology Clinic. Additionally, a grant from the McKesson Foundation allows eligible SNAP/EBT participants to receive $2 worth of produce for every $1 of benefits spent on the farm stand produce.
Massey researcher leads task force to develop first guidelines for evaluating and treating children with thyroid cancer
VCU Massey Cancer Center researcher and Children’s Hospital of Richmond at VCU endocrinologist Gary Francis, M.D., Ph.D., recently led a task force commissioned by the American Thyroid Association (ATA) to develop a set of guidelines for evaluating and treating children with thyroid nodules and cancer. The newly issued guidelines are the first and only set of recommendations aimed at managing patients 18 years of age and younger with thyroid tumors and will provide the best practice standards for diagnosing and treating pediatric thyroid cancer.
Massey becomes the only medical provider in Richmond to offer Interleukin-2 therapy
VCU Massey Cancer Center is now offering FDA-approved Interleukin-2 (IL-2) therapy for metastatic melanoma and metastatic renal cell carcinoma, making Massey the only medical provider in the Richmond area to offer this service. IL-2 treatment is a type of immunotherapy that stimulates the body’s immune system to recognize and kill tumor cells.
Massey researchers find that failure to expand ACA Medicaid coverage would widen disparities in screening uninsured and low-income women for breast and cervical cancer
Virginia Commonwealth University Massey Cancer Center researchers recently conducted a study that found low-income and uninsured women in states that are not expanding their Affordable Care Act (ACA) Medicaid coverage are less likely to receive breast and cervical cancer screenings compared to states that are implementing expansions.
Advanced viral gene therapy eradicates prostate cancer in preclinical experiments
Even with the best available treatments, the median survival of patients with metastatic, hormone-refractory prostate cancer is only two to three years. Driven by the need for more effective therapies for these patients, researchers at VCU Massey Cancer Center and the VCU Institute of Molecular Medicine (VIMM) have developed a unique approach that uses microscopic gas bubbles to deliver directly to the cancer a viral gene therapy in combination with an experimental drug that targets a specific gene driving the cancer’s growth.